Back to Search
Start Over
Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?
- Source :
- Annals of Pharmacotherapy. 51:961-969
- Publication Year :
- 2017
- Publisher :
- SAGE Publications, 2017.
-
Abstract
- Background: Numerous economic models have been published evaluating treatment of chronic hepatitis C virus (HCV) infection, but none provide a comprehensive comparison among new antiviral agents. Objective: Evaluate the cost-effectiveness of all recommended therapies for treatment of genotypes 1 and 4 chronic HCV. Methods: Using data from clinical trials, observational analyses, and drug pricing databases, Markov decision models were developed for HCV genotypes 1 and 4 to compare all recommended drugs from the perspective of the third-party payer over a 5-, 10-, and 50-year time horizon. A probabilistic sensitivity analysis (PSA) was conducted by assigning distributions for clinical cure, age entering the model, costs for each health state, and quality-adjusted life years (QALYs) for each health state in a Monte Carlo simulation of 10 000 repetitions of the model. Results: In the lifetime model for genotype 1, effects ranged from 18.08 to 18.40 QALYs and total costs ranged from $88 107 to $184 636. The lifetime model of genotype 4 treatments had a range of effects from 18.23 to 18.43 QALYs and total costs ranging from $87 063 to $127 637. Grazoprevir/elbasvir was the optimal strategy followed by velpatasvir/sofosbuvir as the second-best strategy in most simulations for both genotypes 1 and 4, with drug costs and efficacy of grazoprevir/elbasvir as the primary model drivers. Conclusions: Grazoprevir/elbasvir was cost-effective compared with all strategies for genotypes 1 and 4. Effects for all strategies were similar with cost of drug in the initial year driving the results.
- Subjects :
- Adult
medicine.medical_specialty
Pathology
Genotype
Cost effectiveness
Cost-Benefit Analysis
Hepacivirus
Antiviral Agents
Drug Costs
Virus
03 medical and health sciences
0302 clinical medicine
Chronic hepatitis
Humans
Medicine
Pharmacology (medical)
030212 general & internal medicine
Intensive care medicine
Aged
Aged, 80 and over
business.industry
Treatment regimen
Hepatitis C
Hepatitis C, Chronic
Middle Aged
medicine.disease
Cost utility
Drug Therapy, Combination
030211 gastroenterology & hepatology
Quality-Adjusted Life Years
business
Subjects
Details
- ISSN :
- 15426270 and 10600280
- Volume :
- 51
- Database :
- OpenAIRE
- Journal :
- Annals of Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....0fe2b6f76695b513b886a3da6249d0d4